Lazard Asset Management
EXAS

Lazard Asset Management’s Exact Sciences EXAS Stock Holding History

Lazard Asset Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,626
Closed -$4.74M – 1940
2025
Q4 		$4.74M Sell
46,626
-74,125
-61% -$5.95M 0.01% 564
2025
Q3 		$6.61M Buy
120,751
+57,350
+90% +$2.87M 0.01% 506
2025
Q2 		$3.37M Sell
63,401
-6,420
-9% -$326K ﹤0.01% 846
2025
Q1 		$3.02M Sell
69,821
-33,546
-32% -$1.7M ﹤0.01% 839
2024
Q4 		$5.81M Buy
103,367
+11,733
+13% +$730K 0.01% 600
2024
Q3 		$6.24M Sell
91,634
-12,116
-12% -$684K 0.01% 577
2024
Q2 		$4.38M Buy
103,750
+42,211
+69% +$2.32M 0.01% 706
2024
Q1 		$4.25M Buy
61,539
+97
+0.2% +$6.14K 0.01% 705
2023
Q4 		$4.54M Sell
61,442
-4,202
-6% -$275K 0.01% 703
2023
Q3 		$4.48M Buy
65,644
+5,925
+10% +$503K 0.01% 720
2023
Q2 		$5.61M Sell
59,719
-88,574
-60% -$6.91M 0.01% 685
2023
Q1 		$10.1M Buy
148,293
+15,953
+12% +$1.03M 0.01% 588
2022
Q4 		$6.55M Sell
132,340
-160,376
-55% -$6.55M 0.01% 659
2022
Q3 		$9.51M Buy
292,716
+52,725
+22% +$2.17M 0.01% 587
2022
Q2 		$9.45M Buy
239,991
+99,739
+71% +$5.33M 0.01% 602
2022
Q1 		$9.81M Buy
140,252
+33,970
+32% +$2.48M 0.01% 621
2021
Q4 		$8.27M Buy
106,282
+20,053
+23% +$1.77M 0.01% 679
2021
Q3 		$8.23M Sell
86,229
-25,057
-23% -$2.65M 0.01% 657
2021
Q2 		$13.8M Buy
111,286
+14,869
+15% +$1.77M 0.02% 526
2021
Q1 		$12.7M Buy
96,417
+80,577
+509% +$11M 0.02% 509
2020
Q4 		$2.1M Buy
+15,840
New +$1.92M ﹤0.01% 789
2020
Q3 		– Sell
-1,887
Closed -$164K – 1644
2020
Q2 		$164K Sell
1,887
-1,261
-40% -$101K ﹤0.01% 945
2020
Q1 		$182K Buy
3,148
+2,250
+251% +$183K ﹤0.01% 912
2019
Q4 		$83K Sell
898
-841
-48% -$73.9K ﹤0.01% 980
2019
Q3 		$156K Buy
1,739
+320
+23% +$36.5K ﹤0.01% 946
2019
Q2 		$167K Buy
+1,419
New +$143K ﹤0.01% 1051
2018
Q2 		– Sell
-42,800
Closed -$1.73M – 1056
2018
Q1 		$1.73M Buy
+42,800
New +$2.09M ﹤0.01% 656

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Lazard Asset Management's EXAS Position: Q1 2026 in Review

Lazard Asset Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 46,626 shares — an estimated $4.74M sold.

Lazard Asset Management first reported a position in EXAS in Q1 2018 and held it in 27 quarters. The position peaked at $13.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Lazard Asset Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 46,626 Exact Sciences shares in Q1 2026, an estimated $4.74M.
  • Lazard Asset Management first reported a position in Exact Sciences in Q1 2018 and held it in 27 quarters.
  • Lazard Asset Management's Exact Sciences position peaked at $13.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.